Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma

Yazmin Odia

Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma

Yazmin Odia

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 2019
Event	Society for NeuroOncology (SNO) 24th Annual Meeting and Education Day - Phoenix, AZ Duration: Nov 1 2019 → …

Conference

Conference	Society for NeuroOncology (SNO) 24th Annual Meeting and Education Day
Period	11/1/19 → …

Disciplines

Medicine and Health Sciences
Neoplasms
Neurology
Oncology

Cite this

@conference{6b6661bbfda34462a2c44e92e436f2fd,

title = "Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma",

author = "Yazmin Odia",

note = "Abstract. ONC201, the first bitopic DRD2 antagonist for clinical oncology, has shown efficacy in H3 K27M-mutant glioma. We performed an integrated preclinical; Society for NeuroOncology (SNO) 24th Annual Meeting and Education Day ; Conference date: 01-11-2019",

year = "2019",

month = nov,

language = "American English",

}

TY - CONF

T1 - Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma

AU - Odia, Yazmin

N1 - Abstract. ONC201, the first bitopic DRD2 antagonist for clinical oncology, has shown efficacy in H3 K27M-mutant glioma. We performed an integrated preclinical

PY - 2019/11

Y1 - 2019/11

UR - https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi186/5620065?redirectedFrom=fulltext

M3 - Presentation

T2 - Society for NeuroOncology (SNO) 24th Annual Meeting and Education Day

Y2 - 1 November 2019

ER -

Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma

Conference

Disciplines

Other files and links

Cite this